Systematic Review

Functional and oncological outcomes with male nerve sparing robotic assisted radical cystectomy

Johnraj Kishore Raja Thinagaran¹, Fouad Maqboul¹, Zach Dovey¹,², Peter Wiklund²

¹Department of Urology, Ashford and St. Peter’s hospital, Chertsey KT16 0PZ, UK.
²Department of Urology, Mount Sinai Hospital, New York, NY 10029, USA.

Correspondence to: Dr. Zach Dovey, Department of Urology, Icahn School of Medicine, Mount Sinai Hospital, 1, Gustav L. Levy Place, New York, NY 10029, USA. E-mail: zachary.dovey@mountsinai.org

How to cite this article: Thinagaran JKR, Maqboul F, Dovey Z, Wiklund P. Functional and oncological outcomes with male nerve sparing robotic assisted radical cystectomy. Mini-invasive Surg 2021;5:46. https://dx.doi.org/10.20517/2574-1225.2021.53

Received: 22 Apr 2021 First Decision: 17 May 2021 Revised: 24 May 2021 Accepted: 26 May 2021 Published: 11 Sep 2021

Academic Editor: Riccardo Autorino Copy Editor: Xi-Jun Chen Production Editor: Xi-Jun Chen

Abstract

Aim: In keeping with the ethos of surgical oncology, male nerve sparing (NS) robotic assisted radical cystectomy (RARC) aims to maximise functional outcomes without sacrificing oncological outcomes. This review details the surgical technique of male NS RARC as well as discussing strategies that may be employed in tandem with surgery to improve post-operative recovery and longer-term quality of life.

Methods: An OVID/EMBASE database search was done with key words of robotic, cystectomy, male and nerve sparing. Publications with no description of post-operative functional outcome were excluded. A total number of 25 relevant publications were selected investigating male NS RARC, assessing functional outcomes along with other surgical standard indicators.

Results: Most series contained small numbers of patients with largely retrospective data and the associated bias of selection. Mean follow up of 27.06 months (range 2.8-58 months) was noted overall. Study design, technique, definitions and measurements of continence and erectile function are heterogeneous across series. With a mean follow up of 27.06 months (range 2.8-58 months), a post-operative satisfactory erectile function of 54.32% (range 9%-100%) and satisfactory day time continence of 90% (range 54.5%-100%) and night time continence of 80.55% (range 46.7%-88%) was found with a mean positive surgical margin rate of only 1.8% (range 0%-6.4%).

Conclusion: Male NS RARC for appropriately selected patients will offer good functional outcomes. Results from the series reviewed suggest the technique is both feasible and safe, without compromising longer term oncological results.
INTRODUCTION

Over 1.72 million people worldwide live with bladder cancer (BC), half of them are from the North America and Europe and men are affected about 4 times more than women[1]. BC accounts for the highest lifetime treatment cost per patient among all cancers, with the United States spending €3.6 billion[2] and Europe another €5 billion[3] per year on the investigation and management of BC. Though there is a decreasing trend in tobacco use in many parts of the world, overall population growth and increasing longevity has led to a rise in BC incidence[4], which shows no signs of abating.

Muscle invasive BCs and occasionally high-grade superficial BCs are managed surgically by radical cystectomy. This is a morbid operation with prolonged recovery time and complications that may be long lasting in some patients. Nevertheless, radical cystectomy has evolved greatly over the years with improvement in knowledge, skills and technology. Marshall and Whitmore[5] provided the first detailed description of a radical cystoprostatectomy and pelvic lymph node dissection in 1949. After Clayman performed the first laparoscopic nephrectomy in 1991, a minimally invasive approach was promoted by urologists for various procedures. More complicated operations like prostatectomy were also performed laparoscopically, but minimally invasive surgery really came into its own when the da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA) came into play[6]. With the advent of robotic assistance in urology and the emergence of robotic assisted radical cystectomy (RARC), allowing better dexterity and visibility, the boundaries have been pushed and expectations have improved.

Although there are similarities in some of the basic technical aspects of nerve sparing (NS) for a radical prostatectomy and a radical cystectomy, there are also some key differences; notwithstanding the potential for urothelial cancer to be more lethal than prostate cancer. This makes patient selection for NS in RARC particularly important. However, there is a reasonable body of evidence establishing the short term (≤5 years) oncologic safety of performing a NS operation for bladder cancers[7,8], which has encouraged Uro-Oncologists to increase the application of this approach in their practice. This review aims to study the technique of male NS RARC, review the results now available in the literature, and examine the status of their functional outcomes and survival outcomes with longer term follow up. Before this, the neuroanatomy of the pelvic plexus will be discussed to provide an understanding of how the technical approach to NS during RARC has developed.

METHODS

Neuroanatomy of the pelvic plexus

The neuroanatomy of the pelvic plexus was originally described in a landmark paper by Walsh and Donker[9] in 1982, studying nerves that supply the penis and pelvic organs in males stillborn at birth. Sympathetic input to pelvic plexus arises from T11-L2 and stimulates ejaculation as well as increasing the bladder neck and urethral tone by inducing contraction of the smooth musculature. Parasympathetic input arises from S2-4 with fibres joining the pelvic plexus and controlling bladder muscle contraction and erectile function. Nerve fibres originating from the pelvic plexus are generally unmyelinated[10]. Tewari further described the surgical neuro-anatomy of the pelvic plexus, dividing it into three distinct zones, that all may be injured during dissection, and thus cause postoperative erectile dysfunction[11]. In broad terms the plexus lies in the subperitoneal tissue near the pelvic ureter and its relation to the vas deferens, and extends forward in a rectangular shape over the lateral and posterior parts of the seminal vesicles (SVs). Its three surgically distinct zones include the proximal neurovascular plate (PNP), containing the cell bodies of the
pelvic plexus, which is in close proximity to the SVs as above, the predominant neurovascular bundle (PNVB) in the groove between posterolateral prostate and rectum, and the accessory nerve pathways (ANPs) on the lateral surface of the prostate in the lateral prostatic fascia\cite{10,11}. During surgical dissection, injury caused by direct trauma or cautery, inflammation, or ischaemia to any of the nerve fibres is potentially reversible, but cell body injuries are not. The pudendal nerve, with somatic cell fibres from Onuf’s nucleus in the anterior horn of S2-4, supplies the pelvic floor muscles and external sphincter. In the context of male NS RARC, this is relevant to neobladder operations, where injury to its nerve branches when dissecting and ligating the dorsal vein complex, may compromise post-operative continence\cite{10}. A detailed knowledge of the neuroanatomy will provide the operating surgeon with direction when dissecting around the SVs, base of prostate and distally towards the prostatic apex, in order to achieve the most effective NS whilst proceeding through the steps of RARC described below.

**Patient preparation and selection**

Patient selection is crucial to surgical planning, especially for the NS approach, with some basic contraindications when considering the RARC part as well as more specific criteria for NS. Moreover, the decision to proceed with NS may be made in conjunction with consideration for orthotopic neobladder, which will also require specific criteria for patient selection. Generally, depending on the surgeon’s experience, relative contraindications to RARC would include BMI > 35, severe vasculopathy with a history of surgery, severe cardiorespiratory illness, prior pelvic trauma, surgery or radiation, and locally advanced disease\cite{12}. For male NS, preoperative potency is a basic requirement, with a desire for ongoing sexual activity postoperatively. Some studies have suggested an age cut off of 65 years, based on poorer recovery in older age groups\cite{13}, but if patients have reasonable preoperative potency, and otherwise are suitable for selection, age should not be a factor in the decision-making process. Positive surgical margin rates have been noted to rise with increasing tumour stage\cite{14}, and clinical tumour stage should be T2 or less. Some groups also suggest clinical evidence of prostate cancer should be a contraindication\cite{15}, but if this has been proven as localized or low volume intermediate risk prostate cancer by preoperative prostate biopsy and multiparametric Magnetic Resonance Imaging prostate, NS may still be undertaken. If orthotopic neobladder is also being considered, patients require unimpaired renal and liver function, no history of urethral sphincter injury, the necessary motivation and cognitive function to undertake the postoperative neobladder training protocols as well as the dexterity to perform intermittent self-catheterization\cite{16}.

Preoperative preparation for patients in modern robotic centres will include application of enhanced recovery after surgery (ERAS) protocols, as well as advice regarding preoperative lifestyle changes and physical activity in what is now termed “prehabilitation”, which aims to maximise postoperative recovery. This is discussed in more detail in the section below. For ERAS protocols, which most robotic centres will have in place, patients are educated and counselled regarding the procedure and recovery, medically optimized, and encouraged to change their diet preoperatively to include carbohydrate loading. Preoperative low residue diet for 24 h with 6 h fasting for solids and 2 h for fluids is also recommended.

**Surgical technique for male RARC**

Applying a modular approach to the technique of male RARC has a number of advantages. It provides a methodical step by step perspective to the procedure that facilitates learning, allows smooth progress through what is a lengthy procedure, allows the operating surgeon be aware of specific steps that may have complications which can be avoided, and ultimately may reduce operating time as experience is gained\cite{12}. Male RARC include the steps of ureteric dissection, dissection of the anterior rectal space, dissection of the lateral rectal space, mobilization of the bladder and urethral transection, extended lymph node dissection (ELND), specimen removal, and urinary diversion. These sections will be discussed individually, before discussing specific techniques for NS (see Figures 1-16).
Following informed consent, once in the operating room the patient receives a general anaesthetic and is then placed in lithotomy position with maximal Trendelenburg tilt. With arms fixed to the side of the body, a pneumatic calf compressor is attached and the upper torso covered by a warming blanket. Broad spectrum antibiotic prophylaxis is administered at induction. Per-urethral bladder catheter is placed. Thromboprophylaxis is given in recovery, and continued for 1 month postoperatively.

**Trocar placement**

This is similar to a robotic prostatectomy, but the trocar placement is shifted cranially. An 8 mm camera port is inserted at a left paramedian point 5-6 cm above the umbilicus, with 2 further 8 mm robotic ports placed 8-10 cm on either side, at the level of umbilicus. A further 8-10 cm lateral to the left port, a 15 mm port is inserted, 2-3 cm superomedial to the left anterior superior iliac spine (ASIS). This is later used to pass the bowel staplers and also serves as the port for the 4th arm. There are 2 other 12 mm assistant ports, one between the camera and the right robotic port and another one 2-3 cm superomedial to the right ASIS\(^1\).
Ureteric dissection
The operation begins with dissection and division of the distal end of the ureters with clips bilaterally, generally first on the right side as the sigmoid colon may be attached to the peritoneum on this side and require adhesiolysis. The ureters can be found entering the pelvis beneath the peritoneum overlying the bifurcation of the common iliac vessels. Incising the peritoneum at this point may reveal their location, and the fourth arm is helpful in retracting the sigmoid colon on the left side. When dissecting distally towards the uretero-vesical junction, it is important to minimize handling of the ureters and leave as much tissue on them as possible to prevent compromising the blood supply and reducing the risk of ureteric strictures long term.

Anterior rectal space
The vasa are localized crossing from lateral to medial beneath the peritoneum, towards the SVs. The fourth arm is used to elevate the peritoneum and then an 8-10 cm incision is made horizontally across the midline below the bladder, extending proximally on either side towards the bifurcation of the common iliac vessels.
The vasa are then divided and the SVs dissected, avoiding cautery and using clips to divide vessels, to avoid injury to the cell bodies of the pelvic plexus. Once Denonvillier’s fascia is exposed, this is divided and the plane posterior to the prostate is opened, continuing down to the pelvic floor. Preserving the fat anterior to the rectum helps to prevent rectal injury.

**Lateral rectal space**
Next the peritoneum lateral to the umbilical ligaments is incised, and retzius space is opened down to the pelvic floor, revealing the endopelvic fascia. The bladder is still attached by the urachus to the anterior abdominal wall and is elevated and put under traction by the fourth arm. Coming back to the lateral pedicle, the superior vesical artery is isolated, and can be divided between Hem-o-lok® clips or by LigaSure™ instrument. The anterior division of the internal iliac artery can be seen, which gives rise to the inferior vesical artery. This then divides into the urethral artery and capsular arteries, the latter of which are preserved because they contribute to the PNVB. The inferior vesical and urethral artery may be clipped or divided by LigaSure™ as above. Moving down to the pelvic floor, the lateral aspects of the prostate are
mobilized and the endopelvic fascia may be opened, which frees the apex of the prostate with puboprostatic ligaments, urethra and dorsal vein complex. This is an area familiar to prostatectomists, and careful dissection in this area is crucial to functional outcomes.

**Urethral transection and mobilisation of the bladder**

The medial umbilical ligament and urachus are divided to free the bladder from the anterior abdominal wall, which allows easier dissection of the prostatic apex. During this part of the procedure, it is important to avoid injury to the inferior epigastric vessels. The pneumoperitoneum is increased to 20 mmHg, and the dorsal vein complex is ligated and divided, revealing the underlying urethra. If an intracorporeal neobladder is planned, urethral transection aims to preserve as much urethral length as possible, and a urethral margin specimen is sent for frozen section to rule out urethral tumour invasion. The urethra with catheter *in situ* is clipped and divided which prevent tumour spillage from the radical cystectomy specimen.
Figure 9. High release of the lateral prostatic fascia containing putative accessory nerve pathways (ANPs), with subsequent dissection of the neurovascular bundle laterally, away from the prostate.

Figure 10. Further dissection of the lateral prostatic fascia and neurovascular bundle laterally, away from the prostate.

Extended lymph node dissection
This is generally performed once the cystectomy is complete so that right and left en bloc lymph node packets can be removed together with the radical cystectomy specimen. The specific technique for ELND is not discussed in this article; suffice to say sparing LNs near the vesico-ureteric junction at superior pedicle will limit injury to the hypogastric nerves carrying sympathetic fibres to the pelvic plexus.\(^{17}\)

Specimen removal
The radical cystectomy specimen is placed in a large endo catch bag, with similar but smaller bags for each lymph node packet. The three bags are clipped together and can be removed through the camera port incision prior to proceeding to the urinary diversion if they are to be sent for biobanking, or alternatively can be removed through the same incision at the end of the procedure.
Urinary diversion
The next step is the urinary diversion, which is commonly either ileal conduit or orthotopic neobladder. The neobladder is in keeping with a NS approach by aiming to maximise functional outcomes with minimal effect on body image, analogous to the pelvic organ sparing approach in women. By avoiding a urostomy bag, as well as reducing the risk of erectile dysfunction as much as possible, the combined result of male NS and neobladder will facilitate a return to sexual activity.

Nerve sparing technique
With the trizonal neuroanatomy described above in mind\(^{[11]}\), the NS technique begins once the SVs dissection starts. Avoidance of cautery and clipping small vessels for hemostasis prevents injury to the cell bodies in the PNP, especially around the middle and the tips of the SVs. As the dissection continues forward, vessels may be clipped as close as possible to the prostate, again avoiding cautery with athermal dissection. Once at the base of the prostate, the lateral fascial layer that contains the ANPs, is divided and released high up on the prostate’s surface and dissected away from the prostate laterally, to prevent injury to
the ANPs. Further inferiorly the PNVB may be seen and is also dissected away from the prostate laterally, with as little tension and cautery as possible. Once this plane is found, dissection continues towards the prostatic apex, with the lateral prostatic fascia and PNVB laterally, down to the pelvic floor, until the prostate-urethral junction. At the apex, the PNVBs run alongside the urethra at 10 and 2 o’clock, and careful suturing of the dorsal vein should avoid these areas, as well as making sure to minimize dissection around the surrounding structures and muscle tissue to prevent injuring branches of the pudendal nerves and accessory vessels[17]. A continuing awareness for nerve preservation is important during the ELND, where sparing lymph nodes at the lateral pedicle between the ureters and bladder near the vesico-ureteric junction prevents injury to the hypogastric nerves carrying sympathetic fibres to the pelvic plexus (described above)[19].

**Technical variations on NS**

Two variations on the common NS approach have also been described including capsule sparing cystectomy and SV sparing cysto-prostatectomy[19]. The capsule sparing technique involves a pre cystectomy
transurethral resection of prostate and prostate biopsies to rule out prostate cancer, followed by RARC with preservation of prostate capsule, vasa and SVs with the trizonal pelvic plexus remaining intact\cite{15,18}. In a prospective randomised controlled trial, no significant difference in functional outcomes was seen between this approach and the commoner NS approach above\cite{19}. For the SV sparing technique, the prostatectomy part of the cysto-prostatectomy is done by retrograde intrafascial dissection sparing the vasa, SVs and once again, the trizonal architecture of the pelvic plexus. This technique was undertaken by some of the series presented in Table 1, with satisfactory outcomes\cite{18,20}, but more study is required to determine whether this technique is superior to the more standard approach.

**RESULTS (SEE Appendix 1, Tables 1 AND 2)**

An EMBASE database search was done with key words of robotic, cystectomy, male and nerve sparing, which included journal articles, abstract publications or conference abstracts, available in English or translated to English. Previous review articles were also checked as sources of original work not otherwise found on initial search. Duplications and publications with no description of post-operative functional
Table 1. Functional outcomes

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Year</th>
<th>Type of study</th>
<th>No. of male patients</th>
<th>Nerve sparing</th>
<th>Continence</th>
<th>Sexual function</th>
<th>Duration of follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balbay et al.</td>
<td>2020</td>
<td>Case series</td>
<td>18</td>
<td>77.78%</td>
<td>DT - 76.92%</td>
<td>Baseline decrease by 15 points</td>
<td>47.3</td>
</tr>
<tr>
<td>Gok et al.</td>
<td>2019</td>
<td>Retrospective analysis</td>
<td>92</td>
<td>90.8%</td>
<td>DT - 65%</td>
<td>Baseline decrease by 24 points</td>
<td>27.1</td>
</tr>
<tr>
<td>Liu et al.</td>
<td>2019</td>
<td>Case series</td>
<td>12</td>
<td>100%</td>
<td>ND</td>
<td>S = 41.7%</td>
<td>12</td>
</tr>
<tr>
<td>Zarranz et al.</td>
<td>2019</td>
<td>Case series - CA</td>
<td>46</td>
<td>67.39%</td>
<td>ND</td>
<td>S = 91% of NS</td>
<td>24</td>
</tr>
<tr>
<td>Kwon et al.</td>
<td>2019</td>
<td>Case series - CA</td>
<td>40</td>
<td>37.5%</td>
<td>ND</td>
<td>40%</td>
<td>12</td>
</tr>
<tr>
<td>Palou et al.</td>
<td>2017</td>
<td>Case report - CA</td>
<td>1</td>
<td>100%</td>
<td>100%</td>
<td>IIEF 17</td>
<td>7</td>
</tr>
<tr>
<td>Asimakopoulos et al.</td>
<td>2016</td>
<td>Case series</td>
<td>40</td>
<td>100%</td>
<td>DT - 75%</td>
<td>77.5%</td>
<td>26.5</td>
</tr>
<tr>
<td>Nyame et al.</td>
<td>2016</td>
<td>Case series</td>
<td>9</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>28.2</td>
</tr>
<tr>
<td>Colombo et al.</td>
<td>2015</td>
<td>Retrospective analysis</td>
<td>90</td>
<td>100%</td>
<td>DT - 88.8%</td>
<td>65%</td>
<td>58</td>
</tr>
<tr>
<td>Jacobs et al.</td>
<td>2015</td>
<td>Randomised controlled trial</td>
<td>40</td>
<td>100%</td>
<td>Baseline decrease by 20 ± 31 points</td>
<td>Baseline decrease by 12 ± 20 points</td>
<td>38</td>
</tr>
<tr>
<td>Schwentner et al.</td>
<td>2015</td>
<td>Retrospective analysis</td>
<td>50</td>
<td>92%</td>
<td>DT - 88%</td>
<td>54% overall</td>
<td>30.3</td>
</tr>
<tr>
<td>Haberman et al.</td>
<td>2014</td>
<td>Retrospective analysis</td>
<td>254</td>
<td>11.42%</td>
<td>ND</td>
<td>S - 45%</td>
<td>32.9</td>
</tr>
<tr>
<td>Menon et al.</td>
<td>2003</td>
<td>Case series - CA</td>
<td>2</td>
<td>100%</td>
<td>ND</td>
<td>I = 100%</td>
<td>2.8</td>
</tr>
<tr>
<td>Krishnan et al.</td>
<td>2014</td>
<td>Case series</td>
<td>3</td>
<td>100%</td>
<td>100%</td>
<td>84.37%</td>
<td>12</td>
</tr>
<tr>
<td>Tyrizitis et al.</td>
<td>2013</td>
<td>Retrospective analysis</td>
<td>62</td>
<td>66.13%</td>
<td>DT - 88.2%</td>
<td>ND</td>
<td>24</td>
</tr>
<tr>
<td>Rey et al.</td>
<td>2013</td>
<td>Case report - CA</td>
<td>1</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>6</td>
</tr>
<tr>
<td>Boc et al.</td>
<td>2013</td>
<td>Case series - CA</td>
<td>2</td>
<td>100%</td>
<td>ND</td>
<td>ND</td>
<td>6.3</td>
</tr>
<tr>
<td>Canda et al.</td>
<td>2012</td>
<td>Case series</td>
<td>25</td>
<td>92%</td>
<td>DT - 73.3%</td>
<td>ND</td>
<td>6.3</td>
</tr>
<tr>
<td>Jonsson et al.</td>
<td>2011</td>
<td>Prospective nonrandomised</td>
<td>36</td>
<td>55%</td>
<td>DT - 83%</td>
<td>75%</td>
<td>25</td>
</tr>
<tr>
<td>Akbulut et al.</td>
<td>2011</td>
<td>Case series</td>
<td>12</td>
<td>91.67%</td>
<td>DT - 54.5%</td>
<td>9%</td>
<td>7.1</td>
</tr>
<tr>
<td>Ong et al.</td>
<td>2010</td>
<td>Case series</td>
<td>31</td>
<td>100%</td>
<td>DT - 93%</td>
<td>79%</td>
<td>18</td>
</tr>
<tr>
<td>Palou et al.</td>
<td>2010</td>
<td>Case series</td>
<td>12</td>
<td>100%</td>
<td>DT - 90.9%</td>
<td>90.9%</td>
<td>16.5</td>
</tr>
<tr>
<td>Murphy et al.</td>
<td>2008</td>
<td>Case series</td>
<td>23</td>
<td>20%</td>
<td>DT - 100%</td>
<td>75%</td>
<td>17</td>
</tr>
<tr>
<td>Mottrie et al.</td>
<td>2007</td>
<td>Case series</td>
<td>27</td>
<td>25.9%</td>
<td>86%</td>
<td>86%</td>
<td>10.2</td>
</tr>
<tr>
<td>Kessler et al.</td>
<td>2004</td>
<td>Retrospective analysis</td>
<td>331</td>
<td>77.34%</td>
<td>DT - 96%</td>
<td>35.93%</td>
<td>24</td>
</tr>
</tbody>
</table>

CA: Conference abstract; ND: not described; DT: day time; NT: night time; S: satisfactory; I: insufficient; N: no erection; NS: nerve sparing.

outcome were excluded. When there was no mention about any sparing of the neurovascular bundles (NVBs), the procedure was taken a non-nerve-sparing procedure and thus also excluded along with the procedures performed without robotic assistance. A total number of 25 relevant publications were selected investigating male NS RARC, assessing functional outcomes with respect to potency and urinary continence along with other surgical standard indicators.
Table 2. Perioperative and oncological outcomes

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Year</th>
<th>No. of male patients</th>
<th>Complications</th>
<th>Positive surgical margins</th>
<th>Survival rates</th>
<th>Duration of follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balbay et al.</td>
<td>2020</td>
<td>18</td>
<td>Early - 9% (≥ Gr3)</td>
<td>13.6%</td>
<td>CSS, OS &amp; RFS at 2 years - 68.6%, 66.0% &amp; 69.7%</td>
<td>47.3</td>
</tr>
<tr>
<td>Gok et al.</td>
<td>2019</td>
<td>92</td>
<td>Early - 20.4% (≥ Gr3)</td>
<td>2%</td>
<td>OS &amp; CSS at 25 months - 20.4% &amp; 13.3%</td>
<td>27.1</td>
</tr>
<tr>
<td>Liu et al.</td>
<td>2019</td>
<td>12</td>
<td>None</td>
<td>Nil</td>
<td>ND</td>
<td>12</td>
</tr>
<tr>
<td>Zarranz et al.</td>
<td>2019</td>
<td>46</td>
<td>Transfusion 35%</td>
<td>Nil</td>
<td>PFS at 2 years 71%</td>
<td>24</td>
</tr>
<tr>
<td>Kwon et al.</td>
<td>2018</td>
<td>40</td>
<td>ND</td>
<td>ND</td>
<td>OS &amp; CSS at 5 years 86.7%</td>
<td>12</td>
</tr>
<tr>
<td>Palou et al.</td>
<td>2017</td>
<td>1</td>
<td>Ileus - 2 days</td>
<td>ND</td>
<td>100%</td>
<td>7</td>
</tr>
<tr>
<td>Asimakopoulos et al.</td>
<td>2016</td>
<td>40</td>
<td>Early - 30%, 2.5% (≥ Gr3) Late - 32.5%, 5% (≥ Gr3)</td>
<td>2.5%</td>
<td>1 death at 23 months</td>
<td>26.5</td>
</tr>
<tr>
<td>Nyame et al.</td>
<td>2016</td>
<td>3</td>
<td>2 (66%) Gr2</td>
<td>Nil</td>
<td>100%</td>
<td>28.2</td>
</tr>
<tr>
<td>Colomba et al.</td>
<td>2015</td>
<td>90</td>
<td>ND</td>
<td>ND</td>
<td>CSS - 92.2%</td>
<td>58</td>
</tr>
<tr>
<td>Jacobs et al.</td>
<td>2015</td>
<td>40</td>
<td>47.5% (≥ Gr3)</td>
<td>5%</td>
<td>ND</td>
<td>38</td>
</tr>
<tr>
<td>Schwentner et al.</td>
<td>2015</td>
<td>50</td>
<td>25.8% (≥ Gr3)</td>
<td>6.4%</td>
<td>CSS - 84% OS - 71%</td>
<td>30.3</td>
</tr>
<tr>
<td>Menon et al.</td>
<td>2003</td>
<td>2</td>
<td>100% Gr1</td>
<td>ND</td>
<td>ND</td>
<td>2.8</td>
</tr>
<tr>
<td>Krishnan et al.</td>
<td>2014</td>
<td>3</td>
<td>ND</td>
<td>Nil</td>
<td>100%</td>
<td>ND</td>
</tr>
<tr>
<td>Tyritzis et al.</td>
<td>2013</td>
<td>62</td>
<td>At 90 days 58.5% overall 37.1% (≥ Gr3)</td>
<td>1.4%</td>
<td>OS &amp; CSS at 2 years 88.9%</td>
<td>12</td>
</tr>
<tr>
<td>Rey et al.</td>
<td>2013</td>
<td>1</td>
<td>None</td>
<td>Nil</td>
<td>100%</td>
<td>24</td>
</tr>
<tr>
<td>Boc et al.</td>
<td>2013</td>
<td>2</td>
<td>ND</td>
<td>Nil</td>
<td>100%</td>
<td>6</td>
</tr>
<tr>
<td>Canda et al.</td>
<td>2012</td>
<td>25</td>
<td>Early - 16% (≥ Gr3) Late - 12% (≥ Gr3)</td>
<td>Nil</td>
<td>CSS - 82.6%, OS - 78.26%</td>
<td>6.3</td>
</tr>
<tr>
<td>Jonsson et al.</td>
<td>2011</td>
<td>36</td>
<td>Early - 40% Late - 33%</td>
<td>2.78%</td>
<td>3 years CSS - 86%</td>
<td>25</td>
</tr>
<tr>
<td>Akbulut et al.</td>
<td>2011</td>
<td>12</td>
<td>16.6% (≥ Gr3)</td>
<td>Nil</td>
<td>CSS - 72.72% OS - 63.63%</td>
<td>7.1</td>
</tr>
<tr>
<td>Ong et al.</td>
<td>2010</td>
<td>31</td>
<td>ND</td>
<td>3.23%</td>
<td>CSS - 96.77%, OS - 93.55%</td>
<td>18</td>
</tr>
<tr>
<td>Palou et al.</td>
<td>2010</td>
<td>12</td>
<td>ND</td>
<td>ND</td>
<td>CSS - 91.67%</td>
<td>16.5</td>
</tr>
<tr>
<td>Murphy et al.</td>
<td>2008</td>
<td>23</td>
<td>26% overall</td>
<td>Nil</td>
<td>1 metastatic death</td>
<td>17</td>
</tr>
</tbody>
</table>

ND: Not described; PFS: progression free survival; OS: overall survival; CSS: cancer specific survival.

**DISCUSSION**

Different approaches have been outlined for male NS RARC\(^{15}\) and this review details the perioperative, oncological and functional outcomes (see Tables 1 and 2). Most series contain small numbers of patients with largely retrospective data with the associated bias of selection. Mean follow up of 27.06 months (range 2.8-58 months) was noted over all in this review. Because of the heterogeneity of study design, technique, definitions and measurements of continence and erectile function and surgeons and centres a meaningful systematic analysis of functional outcomes is challenging.

Though there are differences in defining satisfactory erectile function most encompassing definition derived from all the studies for the purposes of this review was taken as erectile function enough for penetrative sex with or without PDE5i usage. In this review, 54.32% (range 9%-100%) of patients recovered satisfactory erectile function in their post-operative follow up\(^{13,17-38}\). This is superior to the 12%-23.8% satisfactory erectile function noted on patients who underwent a non-NS radical cystectomy\(^{32,36}\).
Continen
te figures are relevant to those patients undergoing orthotopic neobladder at the same time as male NS RARC and satisfactory continence is defined in the studies to be dry enough to maintain with a maximum of one pad per day. In this review, 85.06% day time continence rate (range 54.5%-100%) and 72.48% night time continence rate (range 46.7%-88%) were noted overall in patients whose NVBs were preserved[13,17,18,20-22,26,29-31,33-40]. This is in contrast to the results of some studies, for example, Tyritzis et al.[18], who noted no significant difference in continence rates between their NS and non-NS groups of patients with 88.2% and 88.9% respectively for day time continence rates at 12 months.

With the legitimate concerns for NS being the potential for clinical understaging and incomplete tumour excision, it is of note that overall surgical margin negativity was 98.2% in our review, equivalent to 1.8% positive surgical margins (PSM) (range 0%-6.4%). This compares favourably to other series performing non-NS minimally invasive radical cystectomy achieving 2.2% PSM[41] and an overall 6% found from the results of the International Robotic Cystectomy Consortium[42]. Much of this will be explained by patient selection which rules out pT3-4 tumours, accounting for a significant proportion of PSM cases in other studies.

Examining some of the studies reviewed in more detail, Nyame et al.[26], had a very select patient group of < 40 years old men and performed bilateral nerve and apex sparing radical cystectomy who showed excellent outcomes both oncologically with 0% PSM and 66.7% recurrence free survival and functionally with all their patients being potent and continent after 28.3 months follow up. However, the demographics show that bladder cancer affects much older patients, and once again patient selection is critical. Many patients in their late 60s, early 70s may not regard potency as a priority, but this is not always the case, and although patients below the age of 65 years have better outcomes postoperatively with respect to erectile function, older patients should at least be offered the opportunity to maximise their quality of life after treatment[13]. Canda et al.[40], investigated 27 patients who underwent RARC with Studer Neobladder and found that such procedures, although technically challenging, have good surgical and pathological outcomes and satisfactory morbidity and functional results. They did caution, however, that further studies with more patients and longer follow-ups are necessary[40]. Tyritzis et al.[18], mentioned above, studied functional and oncological outcomes of patients (both male and female) that underwent RARC with totally intracorporeal neobladder. A large proportion of their cohort (41/70; 58.6%) was treated with NS procedures. Sexual function and day time continence at 12-month was satisfactory at between 70% and 90%. They supported the findings of Canda et al.[40], that the complications and both functional and oncological outcomes were comparable to open radical cystectomy, demonstrating that RARC with Robotic neobladder and NS approach is a feasible and safe alternative[36]. Haberman et al.[27], evaluated the effects on post-operative erectile function of a bilateral cavernosal nerve-sparing approach to RARC in a preoperatively potent population. Their retrospective study reviewed data from 254 patients from 2003 to 2012 who had RARC. 29 out of 33 men under the age of 65 years had bilateral nerve-sparing procedure. Postoperatively, 45% of them were able to maintain satisfactory erections for penetrative intercourse with or without use of Viagra type medication. A further 21% recovered erectile function using intracavernosal injections (ICI), while 34% were unable to use ICI or decided recovering their potency was no longer an issue. They further observed no significant difference between those who recovered potency and those who did not based on a number of parameters, including comorbidities, operating time, tumour stage and age of patient. Despite NS, there was no PSMs and no local cancer recurrence. Based on these results, they concluded that NS RARC improved postoperative erectile function without having to compromise oncologic outcomes[27]. Colombo et al.[18], also showed good outcomes in their patient cohort but acknowledged patients were highly selected comprising only 8.8% of all the patients who had a radical cystectomy during the study period. A similar patient cohort demographic was noted by Haberman et al.[27], with only 11.4% of their patients having a NS operation and
14.2% by Ong et al.\textsuperscript{[20]}. Interestingly addressing the issue of potential PSM from incidental prostate cancer in patients undergoing male NS RARC, Chessa et al.\textsuperscript{[43]}, reported no difference in prostate cancer PSM rates.

**Prehabilitation, rehabilitation, adjunctive strategies and lifestyle changes**

ERAS protocols have been gaining in popularity and are now utilized by most robotic urology centres. Surgeons have recognized the importance of preparing patients for a major operation such as an RARC with a multimodal approach, becoming increasingly part of “prehabilitation” programs, aiming to institute lifestyle changes and improve physical fitness before surgery is undertaken. Preoperative smoking cessation has shown to positively impact post-operative outcomes\textsuperscript{[44]}, and, for example, Minella applied prehabilitation tactics in a randomised controlled study group with exercise, nutritional advice and anxiety reducing interventions, finding that patients who went through the program did better than the control group at their 4-week post-operative functional capacity evaluation\textsuperscript{[45]}. Although some of the evidence is conflicting, penile and pelvic floor rehabilitation has been described as part of post-operative follow up for any radical pelvic surgery not only to improve potency but also urinary continence and bowel function postoperatively\textsuperscript{[46]}. In fact, the field of bladder cancer surgery may learn from prostatectomists who employ a number of pre-, intra- and post-operative strategies to improve functional outcomes with both urinary continence and erectile function.

With respect to erectile function, maximizing post-operative recovery begins with pre-operative work up when the patient’s erectile function is assessed objectively. Modalities may include a thorough clinical assessment to stage the disease, IIEF-6 questionnaire, psychosocial assessment including partner factors\textsuperscript{[47]}, sleep assessment\textsuperscript{[48]} and, if necessary, penile doppler ultrasound\textsuperscript{[49]}. Similarly, starting pelvic floor exercises with pelvic floor muscle training (PFMT) before the procedure may benefit post-operative continence in patients undergoing orthotopic neobladder\textsuperscript{[50]}. Intra-operative strategies stress the importance of the accessory pudendal arteries preservation for erectile function\textsuperscript{[51]}, as well as other techniques such as the application of dehydrated human amniotic membrane which has been proposed to accelerate nerve regeneration\textsuperscript{[52]}. Postoperatively a multiple modal approach is advocated for rehabilitation of both erectile and urinary function. Ongoing PFMT as well as biofeedback have been used to improve continence\textsuperscript{[50]}. For penile rehabilitation, strategies include phosphodiesterase-5 inhibitors, intracavernosal injection therapy, vacuum erection devices, MUSE Alprostadil urethral suppository, pelvic floor therapy, penile vibrostimulation, hormonal factor correction, penile implant, hyperbaric oxygen therapy, extracorporeal shockwave therapy, psychosocial therapies and nerve grafting techniques\textsuperscript{[53]}.

Clearly not all of these strategies will apply to bladder cancer patients undergoing male NS RARC with or without neobladder, but by inference, patients will likely have less comorbidities, and be highly motivated to gain as much quality of life functionally after their procedure as possible. The success of these strategies for patients undergoing prostate cancer surgery would suggest these adjunctive treatments are worthy of further investigation for the field of bladder cancer surgery.

In conclusion, male NS RARC for appropriately selected patients, in experienced hands will offer good functional outcomes leading to a better quality of life for those patients who benefit. Results from the series reviewed suggest the technique is both feasible and safe, without compromising longer term oncological results. With the more widespread use of ERAS protocols, and the introduction of prehabilitation and lifestyle programs, patients will also be able to contribute more proactively to their functional recovery, and help with the technical success of the operation. In addition to basic surgical expertise, there are a number of adjunctive strategies aiming to improve urinary and erectile function, and the results demonstrated for
prostate cancer surgery suggests their use in the field of bladder cancer surgery may warrant further investigation.

DECLARATIONS
Authors’ contributions
Performed data analysis, interpretation and manuscript write up: Thinagaran JKR
Technical description of operative steps, data acquisition: Dovey Z
Review of manuscript: Maqboul F
Review and substantial contributions to conception and design of study: Dovey Z, Wiklund P

Availability of data and materials
Tables 1 and 2 provide details of the systematic review. Appendix A PRISMA METHODOLOGY. Figures to illustrate NS technique.

Financial support and sponsorship
None.

Conflicts of interest
Dr. Dovey Z is Medical Director and stock owner (with certificate of shares) of Medtech Holdings Ltd.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
13. Kessler TM, Burkhard FC, Perimenis P. Attempted nerve sparing surgery and age have a significant effect on urinary continence and
40. Canda AE, Atmaca AF, Altinova S, Akbulut Z, Balbay MD. Robot-assisted nerve-sparing radical cystectomy with bilateral extended pelvic lymph node dissection (PLND) and intracorporeal urinary diversion for bladder cancer: initial experience in 27 cases. BJU Int 2012;110:344-44. DOI PubMed

44. Thomsen T, Villebro N, Möller AM. Interventions for preoperative smoking cessation. *Cochrane Database Syst Rev* 2014;CD002294. DOI PubMed PMC


